Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXL1717 vs Docetaxel in Advanced NSCLC
NCT01561456Phase 2Completed
- Sponsor
- Axelar
- Start
- Dec 2011
- Primary completion
- Dec 2013
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of picropodophyllin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Axelar. Primary endpoint: Rate of progression-free survival at 12 weeks. Started Dec 2011; status: completed.
02
Drugs
picropodophyllin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01561456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561456.